Morgan Stanley, CLSA cut Cipla ratings on earnings
MUMBAI (Reuters) - Morgan Stanley and CLSA downgraded their ratings on Cipla Ltd (CIPL.NS) a day after the Indian drugmaker reported a slower-than-expected rise in its October-December net profit.
Morgan Stanley cut its ratings to "equal-weight" from "overweight", citing slower growth prospects on the back of limited niche drug launches, lower margins and a higher tax rate. The bank also cut its price target to 414 rupees from 437 rupees.
CLSA cut its ratings on Cipla to "underperform" from "outperform", citing disappointing margins in the October-December quarter and expectations near-term earnings growth will be slower due a higher base. The bank cut its price target to 415 rupees from 475 rupees.
(Reporting by Abhishek Vishnoi and Rafael Nam; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- Malaysia military tracked missing plane to west coast - source
- Rupee retreats from 7-month high as shares fall
- India halts plan to join global bond indexes, defers Euroclear - sources
- Freescale loss in Malaysia tragedy leads to travel policy questions
- Wild theories fill void left by missing Malaysian plane
MISSING MALAYSIAN PLANE
Malaysia's military believes a jetliner missing for almost four days turned and flew hundreds of kilometres to the west after it last made contact with civilian air traffic control off the country's east coast, a senior officer told Reuters on Tuesday. Full Article | Slideshow
India halts plan to join global bond indexes, defers Euroclear - sources. Full Article
EXCLUSIVE - India to slash Iran oil imports to meet nuclear deal parameters: sources. Full Article